Osteogenesis is improved by low tumor necrosis factor alpha concentration through the modulation of Gs-coupled receptor signals

Molecular and Cellular Biology

Volumn 37, Issue 8, 2017, Pages

  Daniele, Simona ^a   Natali, Letizia ^a   Giacomelli, Chiara ^a   Campiglia, Pietro ^b   Novellino, Ettore ^b   Martini, Claudia ^a   Trincavelli, Maria Letizia ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

A2B adenosine receptor; G protein coupled receptor kinases; Mesenchymal stem cells; Osteoblasts; Proteasome; Tumor necrosis factor alpha

Indexed keywords

ADENOSINE A2B RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; IRON REGULATORY PROTEIN 1; MESSENGER RNA; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR; ADENOSINE A2 RECEPTOR AGONIST; ADRBK1 PROTEIN, HUMAN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; BIOSYNTHESIS; BONE DEVELOPMENT; BONE REMODELING; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; OSTEOBLAST; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; BONE MINERALIZATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; KINETICS; METABOLISM;

ADENOSINE A2 RECEPTOR AGONISTS; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL PROLIFERATION; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; KINETICS; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOGENESIS; RECEPTOR, ADENOSINE A2B; RECEPTORS, G-PROTEIN-COUPLED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85017174934     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00442-16     Document Type: Article

References (59)

1. Office of the Surgeon General. 2004. The burden of bone disease. Bone health and osteoporosis: a report of the surgeon general. Department of Health and Human Services, Rockville, MD. http://www.ncbi.nlm.nih.gov/books/NBK45502/.
2. Marie PJ, Kassem M. 2011. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol 165:1-10. https://doi.org/10.1530/EJE-11-0132.
3. Ai-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einhorn TA. 2008. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res 87:107-118. https://doi.org/10.1177/154405910808700215.
4. Gibon E, Lu L, Goodman SB. 2016. Aging, inflammation, stem cells, and bone healing. Stem Cell Res Ther 22:7-44.
5. Pape HC, Marcucio R, Humphrey C, Colnot C, Knobe M, Harvey EJ. 2010. Trauma-induced inflammation and fracture healing. J Orthop Trauma 24:522-525. https://doi.org/10.1097/BOT.0b013e3181ed1361.
6. Gerstenfeld LC, Cho TJ, Kon T, Aizawa T, Cruceta J, Graves BD, Einhorn TA. 2001. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs 169:285-294. https://doi.org/10.1159/000047893.
7. Kotake S, Nanke Y. 2014. Effect of TNFγ on osteoblastogenesis from mesenchymal stem cells. Biochim Biophys Acta 1840:1209-1213. https://doi.org/10.1016/j.bbagen.2013.12.013.
8. Karnes JM, Daffner SD, Watkins CM. 2015. Multiple roles of tumor necrosis factor-alpha in fracture healing. Bone 78:87-93. https://doi.org/10.1016/j.bone.2015.05.001.
9. Osta B, Benedetti G, Miossec P. 2014. Classical and paradoxical effects of TNF-γ on bone homeostasis. Front Immunol 5:48.
10. Keinan D, Yang S, Cohen RE, Yuan X, Liu T, Li YP. 2014. Role of regulator of G protein signaling proteins in bone. Front Biosci 19:634-648. https://doi.org/10.2741/4232.
11. Graham S, Gamie Z, Polyzois I, Narvani AA, Tzafetta K, Tsiridis E, Helioti M, Mantalaris A, Tsiridis E. 2009. Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: In vivo and in vitro evidence. Expert Opin Investig Drugs 18:746-766.
12. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE. 2001. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054. https://doi.org/10.1210/endo.142.9.8356.
13. Spurney RF, Flannery PJ, Garner SC, Athirakul K, Liu S, Guilak F, Quarles LD. 2002. Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J Clin Investig 109:1361-1371. https://doi.org/10.1172/JCI0214663.
14. Esbrit P, Alcaraz MJ. 2013. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol 85:1417-1423. https://doi.org/10.1016/j.bcp.2013.03.002.
15. Trincavelli ML, Daniele S, Giacomelli C, Taliani S, Da Settimo F, Cosimelli B, Greco G, Novellino E, Martini C. 2014. Osteoblast differentiation and survival: a role for A2B adenosine receptor allosteric modulators. Biochim Biophys Acta 1843:2957-2966. https://doi.org/10.1016/j.bbamcr.2014.09.013.
16. Corciulo C, Wilder T, Cronstein BN. 2016. Adenosine A2B receptors play an important role in bone homeostasis. Purinergic Signal 12:537-547.
17. Carroll SH, Wigner NA, Kulkarni N, Johnston-Cox H, Gerstenfeld LC, Ravid K. 2012. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J Biol Chem 287:15718-15727. https://doi.org/10.1074/jbc.M112.344994.
18. Mediero A, Cronstein BN. 2013. Adenosine and bone metabolism. Trends Endocrinol Metab 24:290-300. https://doi.org/10.1016/j.tem.2013.02.001.
19. Gharibi B, Abraham AA, Ham J, Evans BA. 2011. Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes. J Bone Miner Res 26:2112-2124. https://doi.org/10.1002/jbmr.424.
20. St Hilaire C, Koupenova M, Carroll SH, Smith BD, Ravid K. 2008. TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4. Biochem Biophys Res Commun 375:292-296. https://doi.org/10.1016/j.bbrc.2008.07.059.
21. Kolachala V, Asamoah V, Wang L, Obertone TS, Ziegler TR, Merlin D, Sitaraman SV. 2005. TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis. Cell Mol Life Sci 62:2647-2657. https://doi.org/10.1007/s00018-005-5328-4.
22. Khoa ND, Postow M, Danielsson J, Cronstein BN. 2006. Tumor necrosis factor-alpha prevents desensitization of Galphas-coupled receptors by regulating GRK2 association with the plasma membrane. Mol Pharmacol 69:1311-1319. https://doi.org/10.1124/mol.105.016857.
23. Trincavelli ML, Marroni M, Tuscano D, Ceruti S, Mazzola A, Mitro N, Abbracchio MP, Martini C. 2004. Regulation of A2B adenosine receptor functioning by tumour necrosis factor a in human astroglial cells. J Neurochem 91: 1180-1190. https://doi.org/10.1111/j.1471-4159.2004.02793.x.
24. Wang L, Quarles LD, Spurney RF. 2004. Unmasking the osteoinductive effects of a G protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). J Bone Miner Res 19:1661-1670. https://doi.org/10.1359/JBMR.040708.
25. Spurney RF. 2003. Regulated expression of G protein-coupled receptor kinases (GRK's) and beta-arrestins in osteoblasts. Calcif Tissue Int 73: 153-160. https://doi.org/10.1007/s00223-002-1018-5.
26. Eijkelkamp N, Heijnen CJ, Willemen HL, Deumens R, Joosten EA, Kleibeuker W, den Hartog IJ, van Velthoven CT, Nijboer C, Nassar MA, Dorn GW, Wood JN, Kavelaars A. 2010. GRK2: a novel cell-specific regulator of severity and duration of inflammatory pain. J Neurosci 30:2138-2149. https://doi.org/10.1523/JNEUROSCI.5752-09.2010.
27. Nijboer CH, Heijnen CJ, Willemen HL, Groenendaal F, Dorn GW, van Bel F, Kavelaars A. 2010. Cell-specific roles of GRK2 in onset and severity of hypoxic-ischemic brain damage in neonatal mice. Brain Behav Immun 24:420-426. https://doi.org/10.1016/j.bbi.2009.11.009.
28. Kleibeuker W, Ledeboer A, Eijkelkamp N, Watkins LR, Maier SF, Zijlstra J, Heijnen CJ, Kavelaars A. 2007. A role for G protein-coupled receptor kinase 2 in mechanical allodynia. Eur J Neurosci 25:1696-1704. https://doi.org/10.1111/j.1460-9568.2007.05423.x.
29. Ohba Y, Nakaya M, Watari K, Nagasaka A, Kurose H. 2015. GRK6 phosphorylates I+Bκ at Ser(32)/Ser(36) and enhances TNF-γ-induced inflammation. Biochem Biophys Res Commun 461:307-313. https://doi.org/10.1016/j.bbrc.2015.04.027.
30. Peters DM, Gies EK, Gelb CR, Peterfreund RA. 1998. Agonist-induced desensitization of A2B adenosine receptors. Biochem Pharmacol 55: 873-882. https://doi.org/10.1016/S0006-2952(97)00560-1.
31. Matharu AL, Mundell SJ, Benovic JL, Kelly E. 2001. Rapid agonist-induced desensitization and internalization of the A(2B) adenosine receptor is mediated by a serine residue close to the COOH terminus. J Biol Chem 276:30199-30207. https://doi.org/10.1074/jbc.M010650200.
32. Ribas C, Penela P, Murga C, Salcedo A, García-Hoz C, Jurado-Pueyo M, Aymerich I, Mayor F, Jr. 2007. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signalling. Biochim Biophys Acta 1768:913-922. https://doi.org/10.1016/j.bbamem.2006.09.019.
33. Daniele S, Trincavelli ML, Fumagalli M, Zappelli E, Lecca D, Bonfanti E, Campiglia P, Abbracchio MP, Martini C. 2014. Does GRK-β arrestinmachinery work as a "switch on" for GPR17-mediated activation of intracellular signaling pathways? Cell Signal 26:1310-1325. https://doi.org/10.1016/j.cellsig.2014.02.016.
34. Penela P, Ruiz-Gómez A, Castaño JG, Mayor F, Jr. 1998. Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway. J Biol Chem 273:35238-35244. https://doi.org/10.1074/jbc.273.52.35238.
35. Nogués L, Salcedo A, Mayor F, Jr, Penela P. 2011. Multiple scaffolding functions of (beta)-arrestins in the degradation of G protein-coupled receptor kinase 2. J Biol Chem 286:1165-1173. https://doi.org/10.1074/jbc.M110.203406.
36. Penela P. 2016. Chapter three-ubiquitination and protein turnover of G-protein-coupled receptor kinases in GPCR signaling and cellular regulation. Prog Mol Biol Transl Sci 141:85-140. https://doi.org/10.1016/bs.pmbts.2016.04.002.
37. Li JG, Benovic JL, Liu-Chen LY. 2000. Mechanisms of agonist-induced down-regulation of the human kappa-opioid receptor: internalization is required for down-regulation. Mol Pharmacol 58:795-801.
38. Fumagalli M, Bonfanti E, Daniele S, Zappelli E, Lecca D, Martini C, Trincavelli ML, Abbracchio MP. 2015. The ubiquitin ligase Mdm2 controls oligodendrocyte maturation by intertwining mTOR with G proteincoupled receptor kinase 2 in the regulation of GPR17 receptor desensitization. Glia 63:2327-2339. https://doi.org/10.1002/glia.22896.
39. Varshavsky A. 1997. The ubiquitin system. Trends Biochem Sci 22: 383-387. https://doi.org/10.1016/S0968-0004(97)01122-5.
40. Salcedo A, Mayor F, Jr, Penela P. 2006. Mdm2 is involved in the ubiquitination and degradation of G-protein-coupled receptor kinase 2. EMBO J 25:4752-4762. https://doi.org/10.1038/sj.emboj.7601351.
41. Carotenuto A, Cipolletta E, Gomez-Monterrey I, Sala M, Vernieri E, Limatola A, Bertamino A, Musella S, Sorriento D, Grieco P, Trimarco B, Novellino E, Iaccarino G, Campiglia P. 2013. Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors. Eur J Med Chem 69:384-392. https://doi.org/10.1016/j.ejmech.2013.08.039.
42. Hess K, Ushmorov A, Fiedler J, Brenner RE, Wirth T. 2009. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone 45:367-376. https://doi.org/10.1016/j.bone.2009.04.252.
43. Briolay A, Lencel P, Bessueille L, Caverzasio J, Buchet R, Magne D. 2013. Autocrine stimulation of osteoblast activity by Wnt5a in response to TNF-γ in human mesenchymal stem cells. Biochem Biophys Res Commun 430:1072-1077. https://doi.org/10.1016/j.bbrc.2012.12.036.
44. Ferguson SS, Barak LS, Zhang J, Caron MG. 1996. G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol 74:1095-1110. https://doi.org/10.1139/y96-124.
45. Kohout TA, Lefkowitz RJ. 2003. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 63:9-18. https://doi.org/10.1124/mol.63.1.9.
46. Hock JM, Gera I. 1992. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65-72.
47. Radeff-Huang J, Seasholtz TM, Chang JW, Smith JM, Walsh CT, Brown JH. 2007 Tumor necrosis factor-alpha-stimulated cell proliferation is mediated through sphingosine kinase-dependent Akt activation and cyclin D expression. J Biol Chem 282:863-870. https://doi.org/10.1074/jbc.M601698200.
48. Ghali O, Chauveau C, Hardouin P, Broux O, Devedjian JC. 2010. TNFalpha's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression. J Bone Miner Res 25: 1616-1626. https://doi.org/10.1002/jbmr.52.
49. Trincavelli ML, Daniele S, Martini C. 2010. Adenosine receptors: what we know and what we are learning. Curr Top Med Chem 10:860-877. https://doi.org/10.2174/156802610791268756.
50. Wang L, Liu S, Quarles LD, Spurney RF. 2005. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. Am J Physiol Endocrinol Metab 288:E826-E834.
51. Vroon A, Heijnen CJ, Kavelaars A. 2006. GRKs and arrestins: regulators of migration and inflammation. J Leukoc Biol 80:1214-1221. https://doi.org/10.1189/jlb.0606373.
52. Sinha P, Aarnisalo P, Chubb R, Ono N, Fulzele K, Selig M, Saeed H, Chen M, Weinstein LS, Pajevic PD, Kronenberg HM, Wu JY. 2014. Loss of Gsα early in the osteoblast lineage favors adipogenic differentiation of mesenchymal progenitors and committed osteoblast precursors. J Bone Miner Res 29:2414-2426. https://doi.org/10.1002/jbmr.2270.
53. Penela P, Elorza A, Sarnago S, Mayor F, Jr. 2001. Beta-arrestin-and c-Src-dependent degradation of G protein-coupled receptor kinase 2. EMBO J 20:5129-5138. https://doi.org/10.1093/emboj/20.18.5129.
54. Elorza A, Penela P, Sarnago S, Mayor F, Jr. 2003. MAPK-dependent degradation of G protein-coupled receptor kinase 2. J Biol Chem 278: 29164-29173. https://doi.org/10.1074/jbc.M304314200.
55. Vandesompele J, De Paepe A, Speleman F. 2002. Elimination of primerdimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem 303:95-98. https://doi.org/10.1006/abio.2001.5564.
56. Trincavelli ML, Giacomelli C, Daniele S, Taliani S, Cosimelli B, Laneri S, Severi E, Barresi E, Pugliesi I, Greco G, Novellino E, Da Settimo F, Martini C. 2014. Allosteric modulators of human A2B adenosine receptor. Biochim Biophys Acta 1840:1194-1203. https://doi.org/10.1016/j.bbagen.2013.12.021.
57. Nordstedt C, Fredholm BB. 1990. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem 189:231-234. https://doi.org/10.1016/0003-2697(90)90113-N.
58. Zappelli E, Daniele S, Abbracchio MP, Martini C, Trincavelli ML. 2014. A rapid and efficient immunoenzymatic assay to detect receptor protein interactions: G protein-coupled receptors. Int J Mol Sci 15:6252-6264. https://doi.org/10.3390/ijms15046252.
59. Daniele S, Taliani S, Da Pozzo E, Giacomelli C, Costa B, Trincavelli ML, Rossi L, La Pietra V, Barresi E, Carotenuto A, Limatola A, Lamberti A, Marinelli L, Novellino E, Da Settimo F, Martini C. 2014. Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma. Sci Rep 4:4749.